Abstract: A scaffold-coating design, the hydroxyapatite (HA) porous bone scaffold coated with poly(⑀-)caprolactone (PCL) and HA powder hybrids, was developed for use as tissueregeneration and controlled-release system. An antibiotic drug, tetracycline hydrochloride (TCH), was encapsulated within the hybrid coating layer through a dip-coating and solventcasting method. Coating cycle and drug loading amount differed to control the level of drug-release rate. The HA scaffold framework, obtained by a polymeric foam reticulate method, exhibited a highly porous structure, with porosity and pore size of approximately 87% and 180 m, respectively. The hybrid layer, consisting of PCL sheet and HA fine powders, was uniformly coated on the scaffold surface. The coating layer exhibited only PCL and HA phases and structures, revealing no chemical interaction among the coating components, as observed by X-ray diffraction (XRD) and Fourier-transform infrared (FTIR) analyses. The coated-HA scaffolds showed an effective stress distribution behavior in response to an applied load, as confirmed by the compressive stress-strain curve. The mechanical properties of the coated scaffolds were improved highly with coatings; the compressive strength and elastic modulus of the cyclic coated scaffolds were ϳ3-4 times, and the energy absorption were ϳ8 times, higher than those without coating. These improvements were attributed mainly to the shielding of framework flaws by a flexible coating layer and partially to the thicker stems (porosity reduction). The dissolution of the coated scaffolds in a phosphatebuffered saline (PBS) solution increased with incubation time. The drug was released sharply within the initial several hours (ϳ2 h), but the rate decreased further, showing a sustained release. The release amount was well controlled via coating-cycle and initial drug loading amount, suggesting the effectiveness of the coating-scaffold design as a drug-delivery system.
INTRODUCTION
Over the last a few years, local delivery systems have attracted much attention due to their efficacy to improve the ingrowth and regeneration of bones and teeth. [1] [2] [3] Drugs, such as antibiotics, antitumors, and growth factors, have been administered to defect regions to induce therapeutic effects. [1] [2] [3] A great deal of effort has been exerted to develop drug carriers, in the form of foams, films, and microspheres, aiming at satisfying the requirements, such as safety, greater efficiency, predictable therapeutic response and prolonged release period. [2] [3] [4] [5] [6] As a ceramic carrier, hydroxyapatite (HA) is one of the most attractive systems due to its osteoconductivity and bioactivity. 4 -7 Compared to HA dense body, its porous type has the benefits of a bone scaffold, because it mimics tissue structure and provides high space and surface area for sufficient vascularization and bone ingrowth. Hence, much research has been carried out to design the porous structure and to entrap drugs into the scaffold for a controlled release. [5] [6] [7] However, the drug release was observed to be quite abrupt within initial short periods (less than several hours), and the sustained and prolonged release was not so easily achievable. Moreover, the HA porous scaffolds were so brittle and weak intrinsically that they could not be applied in load-bearing parts. 8 -10 As such, it is important to develop HA scaffolds that possess sustained drug release and mechanical integrity for wider applications.
In this study, a coating design of the HA porous scaffold was proposed to optimize these requirements. The coating layer was intended to be an organic and inorganic hybrid, that is, the poly(⑀-caprolactone) (PCL) polymer and HA ceramic powder. The plastic polymer layer is expected to improve the brittleness of the porous scaffold, and the HA powder was hybridized to enhance biocompatibility and hydrophilicity of the polymer coating layer. 11 The PCL, as a polymer coating component, was used because it is an FDA-cleared biodegradable polymer. In addition, it is cost efficient, and has sustained biodegradation and high permeability for a variety of drugs as compared to other polymers. 12, 13 The HA powder, as an inorganic coating part, was produced by a sol-gel method in order to obtain a uniform and finely mixed coating layer. The HA porous scaffold, fabricated by a polymeric foam reticulate method, was coated with the PCL-HA hybrids after being entrapped with an antibiotic drug tetracycline hydrochloride (TCH). The TCH is a one of the most effective antibiotic drugs with a wide spectrum of antimicrobial activity. Coating cycle and drug amount were varied to offer the system a different level of drugs. Mechanical properties and biological degradation behaviors of the coated scaffolds were investigated. Drug-release profiles of the scaffolds were examined in correlation with their biodegradation and drug diffusion through them. 
MATERIALS AND METHODS

Starting
Fabrication of HA Porous Scaffold
The HA porous scaffold was fabricated by a polyurethane foam reticulate method. 8 Commercially available HA powder was used after calcination at 900°C for 3 h. The powder was suspended in distilled water (DW) at a ratio of HA/DW ϭ50% w/v. The TEPA and PVB, each at 5 % w/v with respect to DW, were added to the HA solution and the mixture was stirred for 24 h to make a viscous HA slurry. The polyurethane foam template was replicated with the slurry by a repeated dipping-and-drying process. The dried body was heat treated stepwise at 600°C for 3 h and further at 1300°C for 3 h. These dipping-to-heat-treating steps were cycled twice, and a HA porous scaffold was obtained. The porosity of the scaffold was ϳ87 %, as obtained by measuring the dimension and weight.
Preparation of HA Sol-Gel Powder
As a coating-layer component, HA powder was synthesized by a sol-gel method. 13 In brief, the CN of 2M was dissolved in ethanol for 24 h. Separately, a TEPI was hydrolyzed in ethanol mixed with distilled water (Ca/P ϭ 1.67 and water/ ethanol ϭ 6 in molar ratio). Both solutions were mixed and stirred for 24 h and then aged at room temperature for 48 h and further at 40°C for 24 h. After being oven dried at 80°C for 24 h, the powder was heat treated at 500°C for 1 h. The obtained powder size was very fine, as measured to be ϳ35 nm on average by transmission electron microscopy (TEM).
14
PCL-HA Hybrid Coatings with Drug Entrapment
PCL tablets were dissolved in DCM by stirring for 6 h at room temperature (PCL/DCM ϭ 8% w/v). Separately, various concentrations of drug TCH were dissolved in DCM, and then stirred for 48 h (TCH/DCM ϭ 0.3, 0.6, and 1.2% w/v). The HA sol-gel powder was added to the TCH solution, and then stirred for 24 h (HA/DCM ϭ 4% w/v). The PCL and HA-TCH solutions were mixed, and then stirred for 24 h. Finally, the TCH loadings within the solution were 2.5, 5, and 10 % w/w with respect to PCLϩHA, and the PCL/HA was 2. For comparison, pure PCL solution without the addition of HA powder was also prepared.
The HA porous scaffolds were dipped into the coating solution, and then immediately rotated to remove the excess solution and to form a uniform coating. The coated scaffolds were oven dried at 40°C for 48 h. The dipping-drying steps were repeated up to three times to obtain a thicker coating layer. In order to observe the efficacy of the cyclic coating, the initial weight of the HA scaffolds differed and its effect on the coating weight gain was investigated.
Characterization and Mechanical Test
Weight change of the porous scaffolds during coating process was measured with the use of an electronic balance (Analytical Balance, BDH). Drug amount within the coating layer was determined in consideration of the total weight change and initial drug ratio within the solution (TCH/PCL ϩ HA ϩ TCH). Phase and structure of the coating layer were characterized with the use of X-ray diffraction (XRD, Philips, Holland) pattern and Fourier-transform infrared (FTIR; System 2000, PerkinElmer) spectroscopy, respectively. Morphology of the coated scaffold was observed with the use of scanning electron microscopy (SEM; Stereoscan S90, Cambridge Ltd., U.K.).
The porous scaffolds prepared with a dimension of approximately 10 ϫ 10 ϫ 5 mm were used for a mechanical test with the use of Instron (Model 4505, U.K.) by applying a compression load at a cross-head speed of 2 mm/min. A stress-strain curve was recorded to determine mechanical properties. Compressive strength and elastic modulus were obtained with the maximum load recorded and the slope at the initial stage (Ͻ 2% strain), respectively. The total energy absorption (W ab ) of a scaffold, defined as the energy necessary to deform a specimen to a strain (⑀), was calculated from the area under the stress-strain curve, as follows.
Four specimens were tested for each condition, and data were represented as mean Ϯ standard deviations (SD).
Coating Degradation and Drug-Release Profile
The coated scaffolds, prepared with weight and dimension of about 1.6 -1.8 g and 20 ϫ 20 ϫ 10 mm, respectively, were used. For comparison, pure HA without the coating layer was also tested. Each specimen was immersed into a beaker containing 100 mL phosphate-buffered saline (PBS, SigmaAldrich, U.K.) solution under 37°C at pH 7.4 for periods up to 7 days. The medium was refreshed every 2 days. At predetermined periods of time, the samples were taken out and dried for 24 h. Apparent weight loss of the scaffold was measured by the weight change during the dissolution test, and data were represented as milligram-per-gram scaffold. The apparent weight loss was also normalized to the initial coating weight to observe the relative weight loss of the coating layer. The release amount of the drug was measured with the use of a UV spectrophotometer (Unicam UV500, ThermoSpectronic, U.K.) at a wavelength of 350 nm. A calibration curve was obtained with TCH concentrations in the range of 0.0015-1 (mg/mL), in which the curve was linear with a relationship of absorbance ϭ 33.43 ϫ concentration (mg/ mL) Ϫ 0.0022. Care was taken for the drug amount to lie within the linear range by means of diluting the solution with additional PBS. With the use of this relationship, the absorbance measured in the test was directly converted to an apparent drug release after dividing the drug release by the initial scaffold weight (milligrams per milliliter per gram of scaffold). The apparent drug release was also normalized to the drug amount initially loaded within the coating layer in order to observe the relative amount of the drug release. The in vitro degradation and drug-release tests were performed in triplicate, and data were represented as mean Ϯ standard deviations (SD).
RESULTS AND DISCUSSION
Coating Morphology and Structure
The typical morphologies of the porous scaffolds before and after hybrid coatings obtained at different coating cycles are shown in Figure 1(A-E) . The bare HA scaffold without coating appeared to replicate the initial polyurethane structure nearly completely [ Figure 1(A) ]. The scaffold had a highly porous structure, consisting of open pore channels and interconnecting framework. The porosity and pore size were measured to be approximately 87% and 150 -200 m, respectively. This morphological feature is expected to provide large surface area and space for sufficient blood circulation and cell ingrowth. 16 On the framework of the porous body, the PCL and HA hybrids were coated [ Figure 1(B-E) ]. Moreover, an antibiotic drug, TCH was loaded at 5% within the coating layer. The coating cycle was altered to load different levels of drugs. With increasing number of coating cycles, the stem became thicker and some pores were partially closed [ Figure 1 . Some nanoscale pores were also observed in the coating layer. The TCH, which could not be discerned easily from the coating layer, might stick to the HA powders or be dispersed into the PCL film. Due to its hydrophilic characteristic, the TCH would bind to the HA powders to a high extent, because the TCH was mixed with the HA powder prior to making a PCL-HA mixture. When the coating cycle was repeated twice, the coating layer covered the surface nearly completely.
The phase and structure of the hybrid coating layer were analyzed with the use of XRD pattern and FTIR spectroscopy, respectively, as shown in Figure 2(A,B) . The hybrid coatings contained 5% TCH. The XRD data clearly showed the existence of only HA and PCL phases [ Figure 2(A) ]. In addition, the coating layer represented typical structural bands of pure PCL (CAO, COO, and CAH) and HA (POO and OOH) [ Figure 2(B) ]. There were few phase and structural changes in the hybrids compared to the pure HA and PCL references. These results suggested that there was little chemical reaction among the coating components (HA, PCL, and TCH).
Weight Change with Cyclic Coating
During the coating process, the weight of the initial scaffolds changed, as shown in Figure 3 . In order to observe the efficacy of the coating process, the initial HA scaffolds were varied in their weights. The TCH amount was 5% with respect to the total coating layer. Data showed a linear increase in the coating weight gain with increasing initial scaffold weight. This confirmed not only that the coating process was consistently carried out without regard to the scaffold weight, but also that the total weight gain of the coating layer is easily predicted from the initial scaffold weight. Practically, the initial weight of the HA scaffold is difficult to control. Hence, the data on the coating weight gain, being linearly related to the initial scaffold weight, is quite useful for the coating design and further administration of drug loading. Figure 4 shows the weight gain of the scaffolds with change in a coating cycle. The coating weight gain increased linearly with increasing coating cycle, suggesting that the coating layer and consequently the drug entrapment could be easily controlled via coating cycle. These results of coating weight gain with respect to scaffold weight and coating cycle confirmed the feasibility and efficacy of the coating method in that the drug entrapment can be predictive and controlled because it is directly proportional to the coating weight gain.
Mechanical Properties
The hybrid coatings influenced the mechanical properties of the HA scaffolds considerably. Figure 5 shows the stressstrain behaviors of the coated scaffolds, responding to an applied load. A compressive load was applied to each sample in a dimension of about 10 ϫ 10 mm ϫ 5 mm at a constant speed until a failure or densification occurred. The pure HA scaffold, tested for comparison, exhibited a typical brittle stress-strain curve, that is, an initial elastic linear region, a maximum stress, and a stress drop followed by an ultimate failure [ Figure 5(A) ]. This stress-strain behavior is easily observed in ceramic foams, which undergo a flaw-associated catastrophic failure. 17, 18 When the sample was coated with PCL-HA hybrid layer at a single cycle, a similar failure behavior was observed [ Figure 5(B) ]. However, as compared to pure HA, the maximum stress was higher and the stress drop region became extended, indicating that the coated scaffold resisted the external load to a high degree. When the coating cycle increased, the scaffolds did not show the catastrophic failure; instead they showed a densification region at strains of about 60 -70%, in which the stress increased abruptly [ Figure 5(C,D) ]. This densification stage was frequently observed in metallic or polymer foams, which undergo a plastic deformation instead of an abrupt failure. 19, 20 The compressive strength (S) and elastic modulus (E) of the scaffolds are quantified from the maximum stress and the initial slope of the stress-strain curve, respectively. More- over, the total energy absorption (W ab ) of the scaffolds was calculated from the area under the stress-strain curve to the failure or densification points, with the use of Eq. (1). Table  I summarizes those mechanical properties. All the mechanical properties (S, E, and W ab ) of coated scaffolds were higher than those of pure HA, and more so with increasing coating cycle. Of special note, compared to strength and elastic modulus, the total energy absorption increased more noticeably with coatings. The total energy absorbed by the scaffold coated three times (14.7 N ⅐ cm) was approximately 8 times higher compared to pure HA (1.79 N ⅐ cm), and the strength and elastic modulus increased by factors of about 4 and 2.5, respectively. The compressive strength and elastic modulus values obtained in this study were quite low and within the margin of natural trabecular bones, presumably due to the high porosities (at least over 80%). Practically, the trabecular bones had mechanical properties in a wide range depending on the porosity, position, and direction, as well as testing methods. [21] [22] [23] The energy-absorption values in the coated scaffolds had higher values than those reported HA scaffolds (4.5-13 N ⅐ cm) with much lower porosities (ϳ60 -70%). 24, 25 Conclusively, the cyclic coating with PCL-HA layer made the brittle HA scaffold absorb energy and redistribute compressive stress more effectively in response to an applied load. Mainly, the flaws in the stem surface were possibly covered and blunted by the flexible coating layer. 26, 27 As a result, the scaffold can respond to the external load more efficiently by redistributing stress to the neighboring stems and absorbing energy through deformation, without showing a flaw-associated fracture. These energy absorption and stress redistribution phenomena are highly favorable in the administration of brittle ceramic materials. At this point, the effect of morphological change should be envisaged. The thicker stems and consequently reduced porosity with cyclic coating also played some role in improving the mechanical properties. However, the coating without the PCL component did not show such an effective energy absorption, although the maximum strength was improved slightly. 8 In this respect, the PCL polymer component is quite beneficial in terms of providing mechanical flexibility and efficient energy absorption.
Biodegradation and Drug Release
The biodegradation and consequently the drug release of the coated scaffolds were investigated in vitro. Figure 6 represents the weight changes of the coated scaffolds with incubation in a phosphate-buffered saline (PBS) solution at 37°C for periods up to 7 days. Apparently, all the coated samples showed a weight loss with incubation time, and the apparent weight loss was higher when the coating cycle increased [ Figure 6(A) ]. The apparent weight loss was normalized with respect to the initial coating weight [ Figure 6 (B)]. Data showed quite different trends from those in Figure 6 (A). The similar weight losses at short periods became different with increasing time; that is, the dissolution rate became lower with cyclic coating at prolonged periods. A more compact structure and thicker layer with cyclic coating resulted in a reduced dissolution amount when normalized to the total coating layer. After 7 days, the weight losses of the coating layers were approximately 15-20%. The weight loss of the coating layer was due to the degradation of both coating components, the HA and PCL, that is, the ionic release of HA and hydrolytic degradation of PCL. The higher water-uptake characteristics of HA surely accelerated the degradation of PCL by means of providing a large amount of water and open structure to the system. 28 Practically, the pure PCL coating was observed to dissolve quite slowly, several times lower than the coatings containing HA. The dissolution of the HA framework without the coating layer was negligible when compared to the coating dissolution.
The dissolution of the coating layer affected the drug release significantly. Figure 7 (A-D) shows the drug amount released from the coating layer for up to 3 days, which was measured with the use of a UV spectrophotometer. The amount of drug entrapped was 5% with respect to the total coating layer. Apparently, the drug was released at a higher rate with increasing coating cycle [ Figure 7(A) ]. This was attributed not only to the larger amount of drugs entrapped but also to the higher degree of apparent coating dissolution [see Figure 6 (A)] of the cyclic coated samples. However, for all coating samples, the apparent release curves behaved similarly, with an initial burst within ϳ2 h and a gradual reduction in release rate thereafter. The change in the release rate with incubation time is easily seen in Figure 7 (B). The initial burst release was a bit higher with increasing coating cycle, which was due to the higher drug loading amount with cyclic coating (data are quantified in Table II ). This initial burst effect was closely related with the abrupt release of the free drugs, which exist on the coating surface without being entrapped efficiently. 29, 30 When the apparent drug release was normalized to the initial drug amount loaded, a similar release rate was observed without regard to the coating cycle, as shown in Figure 7 (C) [compare with Figure 7(A) ]. These normalized data revealed that not only the drug near the surface, but also that deep in the coating layer, diffused out through the diffusion path, such as water channels or pores. In this manner, the drug release was highly affected by the diffusion process, along with the coating degradation. In order to observe the dependence of drug release on the diffusion mechanism, the relative drug release in Figure 7 (C) was plotted with respect to t 1/2 , as shown in Figure 7 (D). Although the data did not show a linear relationship with t 1/2 , the graphs appeared to be less curved when compared to those in Figure 7 (C). Moreover, the curves appeared to consist of several linear segments, and such behavior was frequently observed in composite systems containing degradation materials. 31, 32 Convincingly, it is derived from the results that the drug release was dominated not only by the diffusion of drug through the coating layer, but also by the dissolution of coating components. However, at this point, an exact analysis of the drug release cannot be carried out because it is difficult to simplify the release system due to the complex geometry and mixed release mechanisms. A study on simple hybrid films is currently under way to examine the release mechanism. Figure 8 (A,B) shows the drug releases from the coated scaffolds with different amounts of drug loading. Coating was performed twice, and the TCH amount differed from 2.5 to 10% with respect to the total coating layer. For all periods, the apparent drug amount released was higher when the drug loading amount was higher [ Figure 8(A) ]. For all drug loadings, the release trends were similar, that is, a decrease in release rate with increasing time. When the drug release amount was normalized to the initial amount loaded [ Figure  8 (B)], the difference became much smaller. However, a higher drug loading still showed a higher drug release. Because the drug itself is quite hydrophilic, it absorbs water easily, facilitating the diffusion through the coating layer. 33, 34 In Table II , the drug release amounts at initial (2 h) and prolonged periods (3 days) were quantified. As was explained, increasing the coating cycle and drug loading amount increased the apparent drug release at both initial and prolonged periods. However, when normalized to the drug amounts encapsulated, the difference in release amounts be- came slight, with values being in similar ranges of approximately 15-20 and 20 -25%, after periods of 2 h and 3 days, respectively. As was observed, the drug release from the coating layer was tailored via coating cycle and drug loading amount, and the release behavior was highly affected by both the coating dissolution and the diffusion processes. The dissolution of the coating layer, derived from the hydrolytic degradation of PCL and ionic release of HA, would be one of the main routes by which the drug was released directly, although the drug adhered to and was entrapped within the coating structure efficiently. In addition, the diffusion of drug through the coating structure would be facilitated due to the open structure driven by the water uptake of HA. Based on the efficacy of the coating process, other coating parameters, such as coating composition and concentration, can be tailored to administer the drug release for specific uses. Moreover, other biological polymers, such as poly lactic acid (PLA) and poly glycolic acid (PGA), can be used as coating components to improve mechanical strength and to control degradation rate. For real applications, the coated scaffolds wait for further in vitro antimicrobial assays and in vivo animal tests to evaluate viability and biocompatibility for tissue regeneratives and drug release systems.
CONCLUSIONS
A hydroxyapatite (HA) porous scaffold was coated with poly(⑀-caprolactone) (PCL) and HA hybrids after being entrapped with an antibiotic drug TCH for a controlled release. Coating cycle and drug loading amount were varied to provide a different level of drug release. The mechanical properties of the scaffolds, such as compressive strength, elastic modulus, and energy absorption were improved via the hybrid coatings. The drug was released in a controlled and sustained manner depending on the coating cycle and drug loading amount.
